NEW YORK (GenomeWeb) – Agendia said today that it has signed a marketing agreement with Angsana Molecular & Diagnostics Laboratory for Agendia's MammaPrint and BluePrint breast cancer tests in Southeast Asia.
MammaPrint analyzes 70 genes associated with breast cancer recurrence to provide a binary low or high risk of cancer recurrence to help physicians decide which individuals can forgo chemotherapy. BluePrint includes 80 genes and classifies a patient's breast cancer into one of four functional molecular subtypes.